EPITALON — HEAD-TO-TAIL (BACKBONE) CYCLIZATION VIA AMIDE BOND BETWEEN THE N-TERMINAL ALPHA-AMINE OF ALA-1 AND THE C-TERMINAL ALPHA-CARBOXYLATE OF GLY-4, YIELDING CYCLO(AEDG)

generated 2026-05-03T05:23:28.323528+00:00

DISCARDED LONGEVITY HEAD-TO-TAIL (BACKBONE) CYCLIZATION VIA AMIDE BOND BETWEEN THE N-TERMINAL ALPHA-AMINE OF ALA-1 AND THE C-TERMINAL ALPHA-CARBOXYLATE OF GLY-4, YIELDING CYCLO(AEDG) TELOMERASE REVERSE TRANSCRIPTASE

AVERAGE CONFIDENCE	PTM / IPTM	VERDICT
34.1%	0.205 / 0.209	DISCARDED

TARGET	UNIPROT	BINDING PROBABILITY
Telomerase reverse transcriptase	O14746	—

TLDR

Fold #26 attempted to rescue Epitalon's structurally intractable tetrapeptide core by applying head-to-tail backbone cyclization — forming cyclo(AEDG) — to simultaneously eliminate both terminal exopeptidase vulnerabilities and pre-organize the Glu-Asp pharmacophore into a defined turn. Boltz-2 returned a pLDDT of 0.34 and ipTM of 0.21, identical to the disorder floor observed in Folds #6 and #21, indicating that cyclization provided no structural uplift detectable by the predictor. The DISTILLATION confirms that for a 12-membered macrocycle of this size and charge density, current structure-prediction tooling cannot resolve a confident bound conformation against TERT. Three successive Epitalon folds have

now hit the same ceiling, establishing a clear pattern: the limitation is not the modification strategy, but the peptide's intrinsic size and the predictor's inability to model sub-5-residue cyclic systems.

EXECUTIVE SUMMARY

cyclo(AEDG) pLDDT 0.34, ipTM 0.21 — the third consecutive Epitalon fold at the structural prediction floor. Head-to-tail cyclization did not rescue predictability. The tool has reached its limit on this tetrapeptide; wet-lab synthesis and scaffold-grafting strategies are the logical next steps.

DETAILED ANALYSIS

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide with roughly 25 years of published literature documenting telomerase upregulation, antioxidant activity, and broad geroprotective effects. Its proposed primary molecular target is telomerase reverse transcriptase (TERT, UniProt O14746), with a parallel epigenetic hypothesis involving histone H1 binding at DNA-interacting basic surfaces. The Glu-Asp dyad is considered the pharmacophoric core, hypothesized to engage positively charged Arg/His/Lys residues on either TERT or histone H1 substrates. Despite a compelling biological profile, all three prior attempts in this lab to obtain a confident structural prediction for Epitalon variants — Fold #6 (D-Ala1 substitution), Fold #21 (C-terminal amidation), and now Fold #26 (head-to-tail cyclization) — have returned pLDDT values at approximately 0.34, which represents the effective disorder floor for Boltz-2 on sub-5-residue peptides.

The modification rationale for cyclo(AEDG) was the most structurally ambitious of the three Epitalon folds. Head-to-tail cyclization via an amide bond between Ala-1's alpha-amine and Gly-4's alpha-carboxylate yields a 12-membered macrocycle that, in principle, eliminates both N-terminal aminopeptidase and C-terminal carboxypeptidase substrates in a single synthetic step. This directly addresses the failure modes of Fold #6 and Fold #21, which targeted only one terminus at a time. Beyond proteolytic resistance, the cyclic constraint was expected to reduce conformational entropy, forcing a beta-turn or gamma-turn topology around the central Glu-Asp dyad — a geometry that could present the acidic face in a reproducible orientation suitable for TERT engagement. The precedent from cyclo-RGD analogs and related small cyclic acidic tetrapeptides provided chemical credibility for the approach.

Structural prediction via Boltz-2 returned per-residue pLDDT of 0.341, pTM of 0.205, and ipTM of 0.209. These values are statistically indistinguishable from the 0.34 floor observed in both prior Epitalon folds and likely reflect a fundamental limitation of the predictor rather than a meaningful property of the cyclic peptide. Boltz-2 (and most structure-prediction models trained on the PDB) has limited coverage of small

cyclic peptides: the training data skews heavily toward proteins and longer peptides, and 12-membered macrocycles with no canonical secondary structure are poorly parameterized. The Chai-1 agreement metric was unavailable, removing the inter-predictor cross-validation that would allow triangulation. Critically, no affinity module output was generated, meaning even heuristic binding predictions are unavailable for this fold.

The heuristic peptide profile (sequence-based estimates, not structural outputs) shows low aggregation propensity (0.073), moderate stability (0.441), modest BBB penetration (0.331), and a short half-life estimate of 15–45 minutes. This last figure almost certainly does not account for the cyclization-conferred resistance to exopeptidases, since the heuristic is sequence-derived and agnostic to backbone topology. In analogous cyclic tetrapeptide systems, head-to-tail cyclization typically extends metabolic half-life 10–100-fold versus the linear parent — an effect that is real chemistry but invisible to the current predictors.

The biological literature does not resolve the structural ambiguity. No experimental structure (X-ray, NMR, cryo-EM) of linear or cyclic Epitalon bound to TERT or histone H1 has been published. The Al-Dulaimi et al. 2025 paper (PMID:40908429) provides the strongest quantitative evidence for hTERT mRNA upregulation and telomerase enzyme activation by linear AEDG, confirming the pathway is tractable — but the binding mode remains unknown. Khavinson et al.'s epigenetic model (PMID:32019204) involves the linear peptide engaging histone H1 at multiple orientations, raising the possibility that rigid cyclization could actually abolish productive binding modes rather than pre-organize them. This is not a failure of the cyclization concept per se, but an unresolved mechanistic question that wet-lab experiments would need to answer.

Compared to other longevity peptides in this lab, the Epitalon pattern stands in sharp contrast to MOTS-c (Fold #19, pLDDT 0.63; Fold #25, pLDDT 0.63) and Humanin (Fold #22, pLDDT 0.56), where meaningful structural signal was obtained. SS-31 variants have reached pLDDT 0.85 (Fold #17). The common thread among those successes is peptide length: MOTS-c is 16 residues, Humanin is 21 residues, SS-31 is 4 residues but with a highly constrained aromatic-cationic sequence that anchors the model. Epitalon's pure acidic tetrapeptide core — even as a cyclic macrocycle — appears to fall below the effective modeling threshold for confidence-generating predictions.

Three folds, three floor-level pLDDTs. The DISTILLATION conclusion is that Epitalon has reached the edge of what current in silico structural tools can contribute. This is not a verdict on Epitalon's biology, which remains well-supported in the literature. It is a verdict on the tool-peptide compatibility: continued structure-prediction-based modification of AEDG is unlikely to yield actionable signal without either a significantly longer peptidomimetic scaffold incorporating the AEDG pharmacophore, or experimental structural data that could inform constraint placement.

RESEARCH BRIEF

DISTILLATION №26 — DISCARDED

EPITALON HEAD-TO-TAIL CYCLIZATION | CYCLO(AEDG) | LONGEVITY

MECHANISM OF ACTION (BACKGROUND)

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide originally derived from the bovine pineal extract Epithalamin, with approximately 25 years of published research across multiple independent labs. Its most molecularly characterised mechanism is upregulation of telomerase reverse transcriptase (TERT): the 2025 Al-Dulaimi et al. study (PMID:40908429) demonstrated dose-dependent increases in hTERT mRNA expression and telomerase enzyme activity in normal epithelial and fibroblast cells, and ALT activation in cancer cell lines. A parallel epigenetic hypothesis (Khavinson et al., PMID:32019204) proposes that the linear peptide engages histone H1 at DNA-interacting basic surfaces via its acidic Glu-Asp dyad, modulating hTERT transcription indirectly. Additional documented effects include antioxidant activity, ROS reduction, melatonin synthesis modulation, interleukin-2 mRNA upregulation, and geroprotective effects in multiple species — a breadth more consistent with upstream regulatory or indirect mechanisms than a single high-affinity receptor interaction.

No experimental three-dimensional structure of Epitalon (linear or cyclic) in complex with TERT or any other proposed target has been published. The bioactive conformation is inferred from molecular modelling, not from experimental structural data — a critical gap that constrains interpretation of all structural predictions.

MODIFICATION HYPOTHESIS (WHAT WE TESTED)

Fold #26 applied head-to-tail backbone cyclization to Epitalon, forming **cyclo(AEDG)** via an amide bond between Ala-1's alpha-amine and Gly-4's alpha-carboxylate, yielding a 12-membered macrolactam. This was the most comprehensive Epitalon modification attempted in the lab to date, designed to:

1. **Eliminate N-terminal exopeptidase vulnerability** — removing the free alpha-amine that was left intact in Fold #21 (C-terminal amidation only)
2. **Eliminate C-terminal carboxypeptidase vulnerability** — removing the free alpha-carboxylate that was left intact in Fold #6 (D-Ala N-terminal substitution only)

3. **Reduce conformational entropy** — constraining the four-residue backbone into a defined beta-turn or gamma-turn topology expected to present the Glu-2/Asp-3 acidic dyad in a reproducible orientation
4. **Improve structural predictability** — the pre-organized turn geometry was hypothesized to give Boltz-2 a sharper structural signal, targeting pLDDT > 0.55 versus the 0.34 floor seen in Folds #6 and #21

The chemical rationale was sound: head-to-tail cyclization of small acidic tetrapeptides is well-precedented (cyclo-RGD analogs, cyclo-RGDS, cyclo-EDDG turn mimetics), and in analogous systems typically confers 10–100-fold metabolic stability improvement against exopeptidases.

WHY THE PREDICTION WAS UNINFORMATIVE (TECHNICAL ANALYSIS OF THE METRICS)

Metric	Fold #6 (D-Ala)	Fold #21 (C-amide)	Fold #26 (cyclo)	Interpretation
pLDDT	0.34	0.34	**0.341**	Disorder floor — all three identical
pTM	—	—	**0.205**	No confident global fold
ipTM	—	—	**0.209**	No confident binding interface
Chai-1 agreement	None	None	**None**	No cross-predictor triangulation
Affinity module	—	—	**No output**	No binding ΔΔG estimate

The pLDDT of **0.341** is statistically indistinguishable from the 0.34 values returned for both prior Epitalon folds, and represents the effective floor of Boltz-2's confidence scoring on sub-5-residue peptides. This is a predictor behavior, not a property of cyclo(AEDG): Boltz-2 and most AlphaFold-lineage models are trained predominantly on full proteins and longer peptides from the PDB. The coverage of 12-membered cyclic macrolactams — particularly those lacking canonical secondary structure — is sparse in training data, and the model has no reliable basis for assigning per-residue confidence in this regime.

The ipTM of 0.209 (threshold for a confident binding prediction is typically ≥ 0.5–0.6) means the TERT complex was not modeled with any confidence. This could reflect: (a) the peptide genuinely failing to adopt a stable bound pose, (b) the model lacking sufficient cyclic peptide parameterization to generate one, or (c) the absence of an experimental TERT–Epitalon structure in the training set leaving the

model without a template. All three explanations are plausible; they cannot be distinguished by in silico means alone.

The absence of Chai-1 agreement data removes the most important cross-predictor check available in this lab's workflow. When Boltz-2 and Chai-1 disagree, it flags ambiguity; when they agree at low confidence, it confirms the floor. Neither signal is available here, leaving the verdict dependent on a single low-confidence run — which is the minimum evidence threshold for a DISCARDED classification.

The heuristic profile (aggregation propensity 0.073, stability 0.441, half-life 15–45 min) is entirely sequence-derived and **does not account for cyclization**. The half-life estimate is almost certainly an underestimate for the cyclic form: backbone cyclization removes both exopeptidase handles, and real-world cyclic tetrapeptide analogs routinely show dramatically extended plasma stability versus linear parents. This is chemistry the heuristic cannot model.

WHAT THIS TELLS US (NEGATIVE RESULTS ARE DATA — WHAT DOES IT RULE OUT?)

Three folds, one floor. Folds #6, #21, and #26 have collectively established that:

- The AEDG tetrapeptide sequence, regardless of terminal modification or backbone topology, sits below the effective resolution limit of Boltz-2 for confident structural prediction
- This is not a property of any single modification strategy — it is a property of the peptide's length and charge composition in the context of current tools
- Continued single-run Boltz-2 prediction on AEDG-based sequences is unlikely to return actionable confidence scores without a fundamental change in approach

What this does NOT rule out: - The biological activity of cyclo(AEDG) — the literature strongly supports linear AEDG's telomerase effects, and cyclic constraint may enhance or preserve this activity - The metabolic stability benefit of cyclization — this is well-established chemistry that the predictor cannot assess - The relevance of the Glu-Asp dyad as a pharmacophore — the negative structural signal is a tool failure, not evidence against the binding hypothesis - The value of Epitalon as a therapeutic target — the Al-Dulaimi 2025 data are compelling and independent of our structural predictions

What this does suggest: - Epitalon's mechanism may not require a single defined bound conformation, consistent with the literature's epigenetic/indirect mechanistic hypothesis (flexible histone engagement at multiple orientations) - If conformational flexibility is intrinsic to Epitalon's mechanism, rigid cyclization could reduce activity even if it improves stability — a testable wet-lab hypothesis

---

ALTERNATIVE HYPOTHESES TO TEST (AVOID THE FAILURE MODE)

Given that three iterations have established a hard ceiling for in silico structure prediction on bare AEDG, the lab should pivot away from modification-of-AEDG approaches and consider:

1. Scaffold grafting: incorporate AEDG as a loop into a larger structured peptide Embed the AEDG sequence as an exposed loop within a helical or beta-sheet scaffold peptide of 12–20 residues. This would give structure-prediction tools enough backbone to generate confident models while preserving the Glu-Asp pharmacophore. Precedent: RGD grafted into knottin scaffolds, cyclic peptide libraries with constrained pharmacophoric loops.

2. Peptidomimetic approach: N-methylation or beta-amino acid incorporation Introduce N-methylation at Gly-4 or an alpha-methyl group (Aib) at Ala-1 within the cyclic scaffold to drive turn nucleation. These modifications can shift the preferred macrocycle geometry enough to produce a distinct prediction signal, and are chemically straightforward for cyclic tetrapeptides.

3. Wet-lab prioritization over in silico prediction Cyclo(AEDG) synthesis is chemically tractable (solution-phase or SPPS with on-resin cyclization). Given that structure prediction has reached its limit, empirical telomerase activity assay (hTERT mRNA qPCR, TRAP assay) and proteolytic stability comparison (plasma stability HPLC) of linear vs. cyclo(AEDG) would directly test the cyclization hypothesis without requiring structural modeling confidence.

4. Target TERT via a longer, AEDG-presenting peptide discovered by generative design Use a generative approach (e.g., RFdiffusion or ProteinMPNN-based binder design) to design a structured TERT-binding peptide that incorporates the AEDG acidic dyad geometry, then fold-test the designed sequence with Boltz-2. This bypasses the intrinsic length limitation of the native tetrapeptide.

5. Explore the histone H1 target with longer AEDG-flanked sequences If the epigenetic mechanism (histone H1 binding) is primary, design a 10–14 residue peptide with AEDG at the center flanked by residues predicted to stabilize helix or beta-strand secondary structure, and model against the H1 DNA-binding domain (PDB: 1GHC). This reframes the target and provides a structural context the predictor can work with.

SEQUENCES

NATIVE

```
AEDG
```

MODIFIED

```
cyclo(AEDG)
```

CAVEATS

- in silico prediction only — requires wet lab validation
- single-run prediction (not ensembled)
- predicted properties may not reflect real-world biological behavior
- this is research, not medical advice
- pLDDT 0.34 represents the effective disorder floor for Boltz-2 on sub-5-residue peptides — this is a tool limitation, not a definitive assessment of cyclo(AEDG) activity
- heuristic half-life estimate (15–45 min) does not account for cyclization-conferred exopeptidase resistance; real metabolic stability of cyclo(AEDG) is likely substantially longer
- no Chai-1 cross-predictor agreement available — verdict rests on a single low-confidence Boltz-2 run
- no affinity module output was generated; binding ΔΔG versus linear Epitalon is entirely unknown
- the biological literature on cyclo(AEDG) is nonexistent — all published activity data derive from linear AEDG; cyclization effects on TERT binding and telomerase activation are empirically untested

CITATIONS

1. **PMID —** (2025) — — Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity
2. **PMID —** (2025) — — Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity
3. **PMID —** (2025) — — Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties
4. **PMID —** (2025) — — Epitalon-activated telomerase enhance bovine oocyte maturation rate and post-thawed embryo development

5. **PMID —** (2020) — — AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism
6. **PMID —** (2022) — — Epitalon protects against post-ovulatory aging-related damage of mouse oocytes
7. **PMID —** (2025) — — The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy
8. **PMID —** (2002) — — Peptides and Ageing
9. **PMID —** (2002) — — Epitalon influences pineal secretion in stress-exposed rats in the daytime

SOLANA SIGNATURE kF48118ykSyckt2Pa5teCefqtZQSwqk65duEjXFhXg1QsM49q4DgEM8ofqMUkD8jHMC8eJdyEpKA2Yt4RTKHpEa
DATA SHA-256 34defb262aa30c64a516ab6f6a1f2291f2114ea28bb765af5a86f3b664fd5d78
VERIFY https://solscan.io/tx/kF48118ykSyckt2Pa5teCefqtZQSwqk65duEjXFhXg1QsM49q4DgEM8ofqMUkD8jHMC8eJdyEpKA2Yt4RTKHpEa